- Home
- HURA vs ICG Comparison
HURA vs ICG Comparison
Compare HURA & ICG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURA
- ICG
- Stock Information
- Founded
- HURA 2009
- ICG 2017
- Country
- HURA United States
- ICG China
- Employees
- HURA N/A
- ICG N/A
- Industry
- HURA
- ICG Semiconductors
- Sector
- HURA
- ICG Technology
- Exchange
- HURA Nasdaq
- ICG Nasdaq
- Market Cap
- HURA 126.1M
- ICG 112.7M
- IPO Year
- HURA N/A
- ICG 2023
- Fundamental
- Price
- HURA $2.43
- ICG $1.83
- Analyst Decision
- HURA Strong Buy
- ICG Strong Buy
- Analyst Count
- HURA 2
- ICG 1
- Target Price
- HURA $11.50
- ICG $7.50
- AVG Volume (30 Days)
- HURA 237.9K
- ICG 189.5K
- Earning Date
- HURA 11-13-2025
- ICG 08-14-2025
- Dividend Yield
- HURA N/A
- ICG N/A
- EPS Growth
- HURA N/A
- ICG N/A
- EPS
- HURA N/A
- ICG 0.05
- Revenue
- HURA N/A
- ICG $43,282,895.00
- Revenue This Year
- HURA N/A
- ICG N/A
- Revenue Next Year
- HURA N/A
- ICG $69.92
- P/E Ratio
- HURA N/A
- ICG $38.60
- Revenue Growth
- HURA N/A
- ICG 63.55
- 52 Week Low
- HURA $1.80
- ICG $1.19
- 52 Week High
- HURA $8.40
- ICG $12.04
- Technical
- Relative Strength Index (RSI)
- HURA 43.35
- ICG 41.71
- Support Level
- HURA $2.35
- ICG $1.76
- Resistance Level
- HURA $2.64
- ICG $1.91
- Average True Range (ATR)
- HURA 0.17
- ICG 0.15
- MACD
- HURA -0.03
- ICG 0.02
- Stochastic Oscillator
- HURA 22.03
- ICG 23.26
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
About ICG Intchains Group Limited
Intchains Group Ltd provides integrated solutions consisting of high-performance ASIC chips and ancillary software and hardware for blockchain applications. Its ASIC chips are designed for several key blockchain algorithms including Blake2bsha3, sha512MD160, Cryptonight V4, Eaglesong, Blake2s and others. The company has built a proprietary technology platform named Xihe Platform, which allows the development of a wide range of ASIC chips with high efficiency and scalability. It designs its ASIC chips in-house, which enables it to leverage proprietary silicon data to deliver products reflecting the latest technological developments. Geographically, it operates in Mainland China, Hong Kong, and Other countries or regions.